Skip to main content
. 2023 Jul 19;16:2993–3008. doi: 10.2147/JIR.S416708

Table 2.

Univariate Analysis of Factors Associated with OS and RFS After HSCT

Variate OS RFS
P HR (95% CI) P HR (95% CI)
Age 0.801 1.00(0.97–1.04) 0.83 0.99(0.97–1.02)
Sex 0.867 1.06(0.51–2.21) 0.48 1.24(0.69–2.24)
Disease 0.229 0.61(0.27–1.37) 0.28 0.70(0.37–1.33)
Disease risk (standard vs high) 0.018 2.58(1.18–5.68) 0.04 1.87(1.02–3.43)
Pre-MRD (negative vs positive) <0.01 4.31(1.96–9.47) <0.01 3.13(1.71–5.72)
ATG in conditioning (negative vs positive) 0.348 1.48(0.65–3.33) 0.54 0.83(0.45–1.52)
HLA match (matched vs haplo-matched) 0.409 0.74(0.35–1.53) 0.16 0.66(0.36–1.18)
Blood-type match (matched vs mismatched) 0.643 1.19(0.57–2.46) 0.46 1.25(0.69–2.26)
NK30 (low vs high) 0.001 0.28(0.13–0.61) 0.016 0.48(0.26–0.88)
NK60 (low vs high) 0.008 0.33(0.15–0.76) 0.032 0.51(0.27–0.95)
Graft dose
 CD34+cell 0.071 0.79(0.61–1.02) 0.085 0.84(0.68–1.03)
 MNC 0.053 0.86(0.74–1.00) 0.025 0.87(0.77–0.98)
 CD3+T30 0.133 0.99(0.99–1.00) 0.181 0.99(0.99–1.00)
 CD4+T30 0.445 0.99(0.99–1.00) 0.734 1.00(0.99–1.00)
 CD8+T30 0.138 0.99(0.99–1.00) 0.101 0.99(0.99–1.00)

Abbreviations: OS, Overall survival; RFS, Relapse-free survival; HSCT, Haematopoietic stem cell transplantation; MRD, Minimal residual disease; HR, Hazard ratio; ATG, Anti-thymocyte globulin; HLA, Human leukocyte antigens; MNC, Mononuclear cell.